Virtu Financial LLC acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 48,084 shares of the medical research company's stock, valued at approximately $3,173,000.
Other institutional investors have also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Peoples Bank KS bought a new stake in Edwards Lifesciences during the third quarter worth $40,000. Finally, JFS Wealth Advisors LLC lifted its stake in Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after acquiring an additional 166 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.
Shares of EW opened at $73.78 on Thursday. The business's 50-day moving average price is $68.92 and its 200-day moving average price is $74.19. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The stock has a market cap of $43.52 billion, a PE ratio of 10.65, a P/E/G ratio of 3.52 and a beta of 1.12.
Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts' consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences's revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.59 EPS. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.
In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,262,521.36. This trade represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company's stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares of the company's stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,000 shares of company stock valued at $2,323,150 over the last 90 days. Insiders own 1.27% of the company's stock.
EW has been the topic of a number of recent analyst reports. UBS Group dropped their price target on shares of Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating on the stock in a research report on Tuesday, September 10th. Robert W. Baird dropped their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. upped their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the company a "neutral" rating in a report on Friday, October 25th. Royal Bank of Canada lifted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the stock an "outperform" rating in a report on Thursday, December 5th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $90.00 target price on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $78.65.
View Our Latest Research Report on EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.